Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 133 articles: HTML format

Single Articles

June 2022
1. ABOLHASSANI-CHIMEH R, Akkerman OW, Saktiawati AMI, Punt NC, et al
   Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
   Antimicrob Agents Chemother. 2022 Jun 21:e0000322. doi: 10.1128/aac.00003.
   PubMed     Abstract available
   
   
   
2. WALTER K, Kokesch-Himmelreich J, Treu A, Waldow F, et al
   Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
   Antimicrob Agents Chemother. 2022;66:e0158821.
   PubMed     Abstract available
   
   
   May 2022
3. NUERMBERGER EL, Martinez-Martinez MS, Sanz O, Urones B, et al
   GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
   Antimicrob Agents Chemother. 2022 May 24:e0013222. doi: 10.1128/aac.00132.
   PubMed     Abstract available
   
   
   
4. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
   Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
   Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
   PubMed     Abstract available
   
   
   
5. PAUL A, Nair RR, Jakkala K, Pradhan A, et al
   Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate De Novo Emergence of Genetic Resisters to Antibiotics.
   Antimicrob Agents Chemother. 2022;66:e0228521.
   PubMed     Abstract available
   
   
   
6. CONKLE-GUTIERREZ D, Kim C, Ramirez-Busby SM, Modlin SJ, et al
   Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
   Antimicrob Agents Chemother. 2022 May 9:e0207521. doi: 10.1128/aac.02075.
   PubMed     Abstract available
   
   
   
7. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
   Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
   Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
   PubMed     Abstract available
   
   
   April 2022
8. RAGUNATHAN P, Dick T, Gruber G
   Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.
   Antimicrob Agents Chemother. 2022 Apr 28:e0001822. doi: 10.1128/aac.00018.
   PubMed     Abstract available
   
   
   
9. GARCIA-PRATS AJ, Frias M, van der Laan L, De Leon A, et al
   Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
   Antimicrob Agents Chemother. 2022 Apr 11:e0214421. doi: 10.1128/aac.02144.
   PubMed     Abstract available
   
   
   
10. CHAUHAN U, Barth VC, Woychik NA
    tRNA(fMet) Inactivating Mycobacterium tuberculosis VapBC Toxin-Antitoxin Systems as Therapeutic Targets.
    Antimicrob Agents Chemother. 2022 Apr 11:e0189621. doi: 10.1128/aac.01896.
    PubMed     Abstract available
    
    
    
11. ZHANG T, Yu X, Wen S, Xue Y, et al
    Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.
    Antimicrob Agents Chemother. 2022 Apr 11:e0222421. doi: 10.1128/aac.02224.
    PubMed     Abstract available
    
    
    March 2022
12. TASNEEN R, Garcia A, Converse PJ, Zimmerman MD, et al
    Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Antimicrob Agents Chemother. 2022 Mar 22:e0239821. doi: 10.1128/aac.02398.
    PubMed     Abstract available
    
    
    
13. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    PubMed     Abstract available
    
    
    
14. BASARAB GS, Ghorpade S, Gibhard L, Mueller R, et al
    Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
    Antimicrob Agents Chemother. 2022 Mar 10:e0219221. doi: 10.1128/aac.02192.
    PubMed     Abstract available
    
    
    
15. SHELTON C, McNeil M, Allen R, Flint L, et al
    Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Mar 9:e0204121. doi: 10.1128/aac.02041.
    PubMed     Abstract available
    
    
    January 2022
16. BERG A, Clary J, Hanna D, Nuermberger E, et al
    Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database.
    Antimicrob Agents Chemother. 2022 Jan 31:AAC0179321. doi: 10.1128/AAC.01793.
    PubMed     Abstract available
    
    
    
17. DOMENECH P, Mouhoub E, Reed MB
    Experimental confirmation that an uncommon rrs gene mutation (g878a) of Mycobacterium tuberculosis confers resistance to streptomycin.
    Antimicrob Agents Chemother. 2022 Jan 24:AAC0191521. doi: 10.1128/AAC.01915.
    PubMed     Abstract available
    
    
    
18. KOELE SE, van Beek SW, Maartens G, Brust JCM, et al
    Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment.
    Antimicrob Agents Chemother. 2022 Jan 10:AAC0174921. doi: 10.1128/AAC.01749.
    PubMed     Abstract available
    
    
    December 2021
19. LYONS MA
    Pharmacodynamics and the Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0163621. doi: 10.1128/AAC.01636.
    PubMed     Abstract available
    
    
    
20. KIM JS, Kim YH, Lee SH, Kim YH, et al
    Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0168421. doi: 10.1128/AAC.01684.
    PubMed     Abstract available
    
    
    
21. VERMA R, Gurumurthy M, Yeo BCM, Lu Q, et al
    Effects of increasing concentrations of rifampicin on different Mycobacterium tuberculosis lineages in a Whole blood Bactericidal Activity Assay.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0169921. doi: 10.1128/AAC.01699.
    PubMed     Abstract available
    
    
    November 2021
22. SASAKI T, Svensson EM, Wang X, Wang Y, et al
    Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0160821. doi: 10.1128/AAC.01608.
    PubMed     Abstract available
    
    
    
23. VOGENSEN VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, et al
    Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0182921. doi: 10.1128/AAC.01829.
    PubMed     Abstract available
    
    
    
24. YU JF, Xu JT, Yang SS, Gao MN, et al
    Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0146521. doi: 10.1128/AAC.01465.
    PubMed     Abstract available
    
    
    October 2021
25. GANAPATHY US, Del Rio RG, Cacho-Izquierdo M, Ortega F, et al
    A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0151421. doi: 10.1128/AAC.01514.
    PubMed     Abstract available
    
    
    
26. RADTKE KK, Ernest JP, Zhang N, Ammerman NC, et al
    Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling study.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705.
    PubMed     Abstract available
    
    
    September 2021
27. ALMEIDA D, Converse PJ, Li SY, Upton AM, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0141221. doi: 10.1128/AAC.01412.
    PubMed     Abstract available
    
    
    
28. ABDELWAHAB MT, Wasserman S, Brust JCM, Dheda K, et al
    Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0138121. doi: 10.1128/AAC.01381.
    PubMed     Abstract available
    
    
    August 2021
29. SALAAM-DREYER Z, Streicher EM, Sirgel FA, Menardo F, et al
    Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0036421. doi: 10.1128/AAC.00364.
    PubMed     Abstract available
    
    
    
30. VARGAS R JR, Freschi L, Spitaleri A, Tahseen S, et al
    The role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0116421. doi: 10.1128/AAC.01164.
    PubMed     Abstract available
    
    
    
31. RAI D, Mehra S
    The mycobacterial efflux pump EfpA can induce high drug tolerance to many anti-tuberculosis drugs, including moxifloxacin, in Mycobacterium smegmatis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0026221. doi: 10.1128/AAC.00262.
    PubMed     Abstract available
    
    
    
32. WAGH S, Rathi C, Lukka PB, Parmar K, et al
    Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0174420. doi: 10.1128/AAC.01744.
    PubMed     Abstract available
    
    
    
33. GUO S, Wang B, Fu L, Chen X, et al
    In vitro and in vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 16:AAC0097421. doi: 10.1128/AAC.00974.
    PubMed     Abstract available
    
    
    
34. ROBERTSON GT, Ramey ME, Massoudi LM, Carter CL, et al
    Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0058321. doi: 10.1128/AAC.00583.
    PubMed     Abstract available
    
    
    
35. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    PubMed     Abstract available
    
    
    
36. KIM S, Yamada WM, Duncanson B, Nole J, et al
    Building optimal 3-drug combination chemotherapy regimens to eradicate Mycobacterium tuberculosis in its slow growth acid phase.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0069321. doi: 10.1128/AAC.00693.
    PubMed     Abstract available
    
    
    
37. CUMMING BM, Baig Z, Addicott KW, Chen D, et al
    Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0093221. doi: 10.1128/AAC.00932.
    PubMed     Abstract available
    
    
    July 2021
38. CHIREHWA MT, Court R, de Kock M, Wiesner L, et al
    The effect of isoniazid intake on ethionamide pharmacokinetics and target attainment in multidrug-resistant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Jul 26:AAC0027821. doi: 10.1128/AAC.00278.
    PubMed     Abstract available
    
    
    
39. YU W, Buhari Y, Wang S, Tian X, et al
    Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine and Linezolid in a Murine Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0070621. doi: 10.1128/AAC.00706.
    PubMed     Abstract available
    
    
    
40. VAN SCHIE L, Borgers K, Michielsen G, Plets E, et al
    Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0065921. doi: 10.1128/AAC.00659.
    PubMed     Abstract available
    
    
    
41. ERNEST JP, Sarathy J, Wang N, Kaya F, et al
    Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0050621. doi: 10.1128/AAC.00506.
    PubMed     Abstract available
    
    
    
42. GEWITZ AD, Solans BP, Mac Kenzie WR, Heilig C, et al
    A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0179420. doi: 10.1128/AAC.01794.
    PubMed     Abstract available
    
    
    
43. EGBELOWO O, Sarathy JP, Gausi K, Zimmerman MD, et al
    Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits.
    Antimicrob Agents Chemother. 2021 Jul 6:AAC0002421. doi: 10.1128/AAC.00024.
    PubMed     Abstract available
    
    
    June 2021
44. WERNGREN J, Mansjo M, Glader M, Hoffner S, et al
    Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 28:AAC0072021. doi: 10.1128/AAC.00720.
    PubMed     Abstract available
    
    
    
45. ZENG S, Zhang J, Sun M, Zhang X, et al
    Nitric oxide-dependent electron transport chain inhibition by the cytochrome bc1 inhibitor and pretomanid combination kills Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 21:AAC0095621. doi: 10.1128/AAC.00956.
    PubMed     Abstract available
    
    
    
46. SHETYE GS, Choi KB, Kim CY, Franzblau SG, et al
    In Vitro Profiling of Anti-tubercular Compounds by Rapid, Efficient, and Non-Destructive Assays Using Auto-luminescent Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0028221. doi: 10.1128/AAC.00282.
    PubMed     Abstract available
    
    
    
47. SHIBATA M, Masuda M, Sasahara K, Sasabe H, et al
    Prediction of Human Pharmacokinetic Profiles of the Anti-tuberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value Against Extrapulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0257120. doi: 10.1128/AAC.02571.
    PubMed     Abstract available
    
    
    
48. ZAINABADI K, Walsh KF, Vilbrun SC, Mathurin LD, et al
    Characterization of differentially detectable Mycobacterium tuberculosis in the sputum of subjects with drug sensitive or drug resistant tuberculosis before and after two months of therapy.
    Antimicrob Agents Chemother. 2021 Jun 1:AAC0060821. doi: 10.1128/AAC.00608.
    PubMed     Abstract available
    
    
    May 2021
49. JOHANSEN MD, Shalini, Kumar S, Raynaud C, et al
    Biological and biochemical evaluation of isatin-isoniazid hybrids as bactericidal candidates against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00011.
    PubMed     Abstract available
    
    
    
50. MOK S, Roycroft E, Flanagan PR, Montgomery L, et al
    Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis isolates.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.02617.
    PubMed     Abstract available
    
    
    
51. WASSERMAN S, Davis A, Stek C, Chirehwa M, et al
    Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00140.
    PubMed     Abstract available
    
    
    April 2021
52. SONNENKALB L, Strohe G, Dreyer V, Andres S, et al
    Microevolution of Mycobacterium tuberculosis hetero-resistance subpopulations in a patient receiving 27 years of tuberculosis treatment in Germany.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02520.
    PubMed     Abstract available
    
    
    
53. TASNEEN R, Mortensen DS, Converse PJ, Urbanowski ME, et al
    Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.00253.
    PubMed     Abstract available
    
    
    
54. LEY SD, Pillay S, Streicher EM, van der Heijden YF, et al
    Melting the Eis: non-detection of kanamycin resistance markers by routine diagnostic tests and identification of new eis-promoter variants.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02502.
    PubMed     Abstract available
    
    
    
55. ABDELWAHAB MT, Court R, Everitt D, Diacon AH, et al
    The effect of Clofazimine Concentration on QT prolongation in patients treated for tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.02687.
    PubMed     Abstract available
    
    
    
56. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    PubMed     Abstract available
    
    
    
57. LIN WH, Lee WT, Tsai HY, Jou R, et al
    Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes.
    Antimicrob Agents Chemother. 2021 Apr 12. pii: AAC.01573.
    PubMed     Abstract available
    
    
    March 2021
58. ARDIZZONI E, Ariza E, Mulengwa D, Mpala Q, et al
    Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02263.
    PubMed     Abstract available
    
    
    
59. MODLIN SJ, Marbach T, Werngren J, Mansjo M, et al
    Atypical Genetic Basis of Pyrazinamide Resistance in Mono-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.01916.
    PubMed     Abstract available
    
    
    February 2021
60. OMOLLO C, Singh V, Kigondu E, Wasuna A, et al
    Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02554.
    PubMed     Abstract available
    
    
    
61. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
    Deletion of Rv2571c confers resistance to arylamide compounds in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02334.
    PubMed     Abstract available
    
    
    
62. VILCHEZE C, Jacobs WR Jr
    The promises and limitations of N-acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.01703.
    PubMed     Abstract available
    
    
    
63. LUN S, Xiao S, Zhang W, Wang S, et al
    Therapeutic potential of coumestan Pks13 inhibitors for tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02190.
    PubMed     Abstract available
    
    
    
64. PIETERMAN ED, van den Berg S, van der Meijden A, Svensson EM, et al
    Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02255.
    PubMed     Abstract available
    
    
    
65. XU J, Converse PJ, Upton AM, Mdluli K, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02418.
    PubMed     Abstract available
    
    
    January 2021
66. HO VQT, Verboom T, Rong MK, Habjan E, et al
    Heterologous expression of ethA and katG in Mycobacterium marinum enables the rapid identification of new prodrugs active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jan 25. pii: AAC.01445.
    PubMed     Abstract available
    
    
    
67. DRUSANO GL, Kim S, Almoslem M, Schmidt S, et al
    The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available
    
    
    
68. KHAN MZ, Nandicoori VK
    Deletion of PknG abates reactivation of latent Mycobacterium tuberculosis in mice.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02095.
    PubMed     Abstract available
    
    
    
69. DRUSANO GL, Rogers S, Brown D, Peloquin CA, et al
    Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02533.
    PubMed     Abstract available
    
    
    
70. ZHU H, Fu L, Wang B, Chen X, et al
    Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis, in different administration intervals in mouse tuberculosis models.
    Antimicrob Agents Chemother. 2021 Jan 11. pii: AAC.02164.
    PubMed     Abstract available
    
    
    December 2020
71. VALAFAR SJ
    A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02091.
    PubMed     Abstract available
    
    
    
72. LIN SY, Feng JY, Lee CY, Lin YC, et al
    Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02184.
    PubMed     Abstract available
    
    
    November 2020
73. VIJAY S, Nhung HN, Bao NLH, Thu DDA, et al
    Most-probable number based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01439.
    PubMed     Abstract available
    
    
    
74. IGNATIUS EH, Abdelwahab MT, Hendricks B, Gupte N, et al
    Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2020 Nov 23. pii: AAC.01196.
    PubMed     Abstract available
    
    
    
75. PANJASAWATWONG N, Wattanakul T, Hoglund RM, Bang ND, et al
    Population pharmacokinetic properties of anti-tuberculosis drugs in Vietnamese children with tuberculous meningitis.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00487.
    PubMed     Abstract available
    
    
    
76. GRZEGORZEWICZ AE, Lelievre J, Esquivias J, Angala B, et al
    Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01914.
    PubMed     Abstract available
    
    
    October 2020
77. ARUN KB, Madhavan A, Abraham B, Balaji M, et al
    Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.00456.
    PubMed     Abstract available
    
    
    
78. WILLBY M, Chopra P, Lemmer D, Klein K, et al
    Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
    PubMed     Abstract available
    
    
    
79. MALLIKAARJUN S, Chapagain ML, Sasaki T, Hariguchi N, et al
    Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Pulmonary Multidrug-Resistant Tuberculosis Patients.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01207.
    PubMed     Abstract available
    
    
    
80. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    PubMed     Abstract available
    
    
    
81. RIFAT D, Li SY, Ioerger T, Shah K, et al
    Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01948.
    PubMed     Abstract available
    
    
    
82. SATHKUMARA HD, Hansen K, Miranda-Hernandez S, Govan B, et al
    Disparate effects of metformin on Mycobacterium tuberculosis infection in diabetic and non-diabetic mice.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.01422.
    PubMed     Abstract available
    
    
    
83. VAN DER WALT ML, Shean K, Becker P, Keddy KH, et al
    Treatment outcomes and adverse drug effects of ethambutol, cycloserine and terizidone for treatment of multi-drug resistant tuberculosis in South Africa.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00744.
    PubMed     Abstract available
    
    
    September 2020
84. DRUSANO GL, Duncanson B, Scanga CA, Kim S, et al
    Developing new drugs for the therapy of Mycobacterium tuberculosis: What information do we get from pre-clinical animal models?
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01376.
    PubMed     Abstract available
    
    
    
85. LI M, Nyantakyi SA, Go ML, Dick T, et al
    Resistance against membrane-inserting MmpL3 inhibitor through upregulation of MmpL5 in M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01100.
    PubMed     Abstract available
    
    
    August 2020
86. REICHMUTH ML, Homke R, Zurcher K, Sander P, et al
    Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naive Patients.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00513.
    PubMed     Abstract available
    
    
    
87. CHIREHWA MT, Court R, De Kock M, Wiesner L, et al
    Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone.
    Antimicrob Agents Chemother. 2020 Aug 17. pii: AAC.01381.
    PubMed     Abstract available
    
    
    
88. ALGHAMDI WA, Al-Shaer MH, An G, Alsultan A, et al
    Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimens Simulation and Target Attainment Analysis.
    Antimicrob Agents Chemother. 2020 Aug 10. pii: AAC.01174.
    PubMed     Abstract available
    
    
    July 2020
89. LOISEAU C, Brites D, Reinhard M, Zurcher K, et al
    HIV coinfection is associated with low fitness rpoB variants in rifampicin-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 27. pii: AAC.00782.
    PubMed     Abstract available
    
    
    
90. MARIOTTI S, Teloni R, de Turris V, Pardini M, et al
    Amphotericin B inhibits Mycobacterium tuberculosis infection of human alveolar type II epithelial A549 cells.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01164.
    PubMed     Abstract available
    
    
    
91. AL-SHAER MH, Martson AG, Alghamdi WA, Alsultan A, et al
    Ethionamide population pharmacokinetic model and target attainment in multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00713.
    PubMed     Abstract available
    
    
    
92. VILCHEZE C, Saranathan R, Weinrick B, Jacobs WR Jr, et al
    Characterization of large deletion mutants of Mycobacterium tuberculosis selected for isoniazid resistance.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00792.
    PubMed     Abstract available
    
    
    June 2020
93. SAFI H, Lingaraju S, Ma S, Husain S, et al
    Rapidly-correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small Colony Variant Morphology.
    Antimicrob Agents Chemother. 2020 Jun 22. pii: AAC.00213.
    PubMed     Abstract available
    
    
    
94. COHEN KA, Stott KE, Munsamy V, Manson AL, et al
    Evidence for expanding the role of streptomycin in the management of drug-resistant M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00860.
    PubMed     Abstract available
    
    
    May 2020
95. LI Y, Dong W, Lan T, Fan J, et al
    Distribution of linezolid in tuberculosis lesions in patients with spinal multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00450.
    PubMed     Abstract available
    
    
    
96. KIM HY, Srivastava S, Kumar Ak H, Marais BJ, et al
    Optimal dose or optimal exposure? Consideration for linezolid in tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00287.
    PubMed     Abstract available
    
    
    
97. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00709.
    PubMed     Abstract available
    
    
    April 2020
98. PIETERMAN ED, Sarink MJ, Sala C, Cole ST, et al
    Advanced quantification methods to improve the 18b dormancy model for assessing the activity of tuberculosis drugs in vitro.
    Antimicrob Agents Chemother. 2020 Apr 27. pii: AAC.00280.
    PubMed     Abstract available
    
    
    
99. FARAJ A, Svensson RJ, Diacon AH, Simonsson USH, et al
    Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available
    
    
    
100. HAYASHI M, Nishiyama A, Kitamoto R, Tateishi Y, et al
     Adduct Formation of Delamanid with NAD in Mycobacteria.
     Antimicrob Agents Chemother. 2020;64.
     PubMed     Abstract available
     
     
     
101. NARMANDAKH E, Tumenbayar O, Borolzoi T, Erkhembayar B, et al
     Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.
     Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00537.
     PubMed     Abstract available
     
     
     March 2020
102. HARIGUCHI N, Chen X, Hayashi Y, Kawano Y, et al
     OPC-167832, a novel carbostyril derivative with potent anti-tuberculosis activity as a DprE1 inhibitor.
     Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02020.
     PubMed     Abstract available
     
     
     
103. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
     Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
     Antimicrob Agents Chemother. 2020;64.
     PubMed    
     
     
     
104. ENKIRCH T, Werngren J, Groenheit R, Alm E, et al
     Systematic review of whole genome sequencing data to predict phenotypic drug resistance and susceptibility in Swedish Mycobacterium tuberculosis isolates 2016-2018.
     Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02550.
     PubMed     Abstract available
     
     
     February 2020
105. RABIE H, Tikiso T, Lee J, Fairlie L, et al
     Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
     Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
     PubMed     Abstract available
     
     
     
106. WALSH KF, McAulay K, Lee MH, Vilbrun SC, et al
     Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01956.
     PubMed     Abstract available
     
     
     
107. GENGENBACHER M, Zimmerman MD, Sarathy JP, Kaya F, et al
     Tissue distribution of doxycycline in animal models of tuberculosis.
     Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02479.
     PubMed     Abstract available
     
     
     January 2020
108. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
     Correction for Kempker et al., "A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment".
     Antimicrob Agents Chemother. 2020;64.
     PubMed    
     
     
     
109. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
     Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02012.
     PubMed     Abstract available
     
     
     
110. REINGEWERTZ TH, Meyer T, McIntosh F, Sullivan J, et al
     Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
     Antimicrob Agents Chemother. 2020;64.
     PubMed     Abstract available
     
     
     
111. MTHIYANE T, Millard J, Adamson J, Balakrishna Y, et al
     N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
     Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376.
     PubMed     Abstract available
     
     
     
112. WASSERMAN S, Huo S, Ky K, Malig YN, et al
     CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.
     Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145.
     PubMed     Abstract available
     
     
     
113. ZHANG N, Strydom N, Tyagi S, Soni H, et al
     Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
     Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01727.
     PubMed     Abstract available
     
     
     
114. JING W, Zong Z, Tang B, Wang J, et al
     Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
     Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01736.
     PubMed     Abstract available
     
     
     December 2019
115. BJUGARD NYBERG H, Draper HR, Garcia-Prats AJ, Thee S, et al
     Population pharmacokinetics and dosing of ethionamide in children with tuberculosis.
     Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01984.
     PubMed     Abstract available
     
     
     
116. ELINGS W, Gaur A, Blok AJ, Timmer M, et al
     beta-Lactamase of Mycobacterium tuberculosis shows dynamics in the active site that increase upon inhibitor binding.
     Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.02025.
     PubMed     Abstract available
     
     
     
117. ABDELWAHAB MT, Leisegang R, Dooley KE, Mathad JS, et al
     Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV.
     Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01978.
     PubMed     Abstract available
     
     
     November 2019
118. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
     Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
     Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01583.
     PubMed     Abstract available
     
     
     October 2019
119. DONNELLAN S, Aljayyoussi G, Moyo E, Ardrey A, et al
     Intracellular pharmacodynamic modelling (PDi) is predictive of the clinical activity of fluoroquinolones against Tuberculosis.
     Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.00989.
     PubMed     Abstract available
     
     
     
120. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
     A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.
     Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215.
     PubMed     Abstract available
     
     
     September 2019
121. LYONS MA
     Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.
     Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.00732.
     PubMed     Abstract available
     
     
     August 2019
122. SALINGER DH, Subramoney V, Everitt D, Nedelman JR, et al
     Population Pharmacokinetics of Pretomanid.
     Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00907.
     PubMed     Abstract available
     
     
     
123. TUCKER EW, Pieterse L, Zimmerman MD, Udwadia ZF, et al
     Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
     Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.00913.
     PubMed     Abstract available
     
     
     July 2019
124. ENIMIL A, Antwi S, Yang H, Dompreh A, et al
     Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old.
     Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00839.
     PubMed     Abstract available
     
     
     May 2019
125. MALIK AA, Brooks MB, Siddiqui S, Fuad J, et al
     Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     
126. GHIMIRE S, Maharjan B, Jongedijk EM, Kosterink JGW, et al
     Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     March 2019
127. ISMAIL N, Peters RPH, Ismail NA, Omar SV, et al
     Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     
128. MUSTAZZOLU A, Venturelli L, Dinarelli S, Brown K, et al
     A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria.
     Antimicrob Agents Chemother. 2019;63.
     PubMed     Abstract available
     
     
     January 2019
129. FRANCIS J, Zvada SP, Denti P, Hatherill M, et al
     Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
     Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01964.
     PubMed     Abstract available
     
     
     
130. RICHARD M, Gutierrez AV, Viljoen A, Rodriguez-Rincon D, et al
     Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
     Antimicrob Agents Chemother. 2018;63.
     PubMed     Abstract available
     
     
     November 2018
131. KWARA A, Yang H, Antwi S, Enimil A, et al
     Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.
     Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657.
     PubMed     Abstract available
     
     
     September 2018
132. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
     A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
     Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
     PubMed     Abstract available
     
     
     May 2018
133. YEW WW, Chang KC, Chan DP
     Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
     Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: